447 related articles for article (PubMed ID: 26458498)
1. Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression.
Shah AP; Chen JM; Fridell JA
Clin Transplant; 2015 Dec; 29(12):1221-9. PubMed ID: 26458498
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.
Fallatah SM; Marquez MA; Bazerbachi F; Schiff JR; Cattral MS; McGilvray ID; Norgate A; Selzner M; Rotstein C; Husain S
Clin Transplant; 2013; 27(4):503-9. PubMed ID: 23731387
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
4. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
Lo A; Stratta RJ; Egidi MF; Shokouh-Amiri MH; Grewal HP; Kisilisik AT; Trofe J; Alloway RR; Gaber LW; Gaber AO
Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
[TBL] [Abstract][Full Text] [Related]
5. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation.
Kaufman DB; Leventhal JR; Gallon LG; Parker MA; Koffron AJ; Fryer JP; Abecassis MM; Stuart FP
Transplantation; 2001 Dec; 72(12):1940-5. PubMed ID: 11773893
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of cytomegalovirus infection after pancreas transplantation.
Parsaik AK; Bhalla T; Dong M; Rostambeigi N; Dierkhising RA; Dean P; Abraham R; Prieto M; Kremers WK; Razonable RR; Kudva YC
Transplantation; 2011 Nov; 92(9):1044-50. PubMed ID: 21904269
[TBL] [Abstract][Full Text] [Related]
7. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
[TBL] [Abstract][Full Text] [Related]
8. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S
Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus infection in heart transplantation: A single center experience.
Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
[TBL] [Abstract][Full Text] [Related]
10. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.
Limaye AP; Corey L; Koelle DM; Davis CL; Boeckh M
Lancet; 2000 Aug; 356(9230):645-9. PubMed ID: 10968438
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
12. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
Cervera C; Pineda M; Linares L; Marcos MA; Esteva C; Antón A; Cofán F; Ricart MJ; Navasa M; Pérez-Villa F; Pumarola T; Moreno A
Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis.
Rayes N; Seehofer D; Kahl A; Kokott S; Pratschke J; Frei U; Neuhaus P
Transpl Int; 2007 Nov; 20(11):974-81. PubMed ID: 17680782
[TBL] [Abstract][Full Text] [Related]
14. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
15. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients.
Luan FL; Chopra P; Park J; Norman S; Cibrik D; Ojo A
Transplant Proc; 2006 Dec; 38(10):3673-5. PubMed ID: 17175363
[TBL] [Abstract][Full Text] [Related]
17. Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients.
Axelrod D; Leventhal JR; Gallon LG; Parker MA; Kaufman DB
Am J Transplant; 2005 Jun; 5(6):1423-9. PubMed ID: 15888050
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus infection in simultaneous pancreas-kidney transplantation.
Malaise J; Ricart MJ; Moreno A; Crespo M; Fernández-Cruz L; Van Ophem D; Squifflet JP;
Transplant Proc; 2005; 37(6):2848-50. PubMed ID: 16182830
[TBL] [Abstract][Full Text] [Related]
19. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
Jewani PK; Pouch SM; Kissling KT
Clin Transplant; 2018 Nov; 32(11):e13420. PubMed ID: 30290013
[TBL] [Abstract][Full Text] [Related]
20. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.
Luan FL; Samaniego M; Kommareddi M; Park JM; Ojo AO
Transpl Infect Dis; 2010 Dec; 12(6):473-9. PubMed ID: 20576019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]